Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Part 1 And 2: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs) |
|
Cycle 1 (Up to 28 days for non-hematologic DLTs and up to 42 days for hematologic DLTs) |
|
Primary |
Part 1 And 2: Number Of Participants Receiving BGB-11417 In Combination With Azacitidine Experiencing Treatment-emergent Adverse Events (TEAEs) |
|
Approximately 24 months |
|
Primary |
Part 3 AML Cohort: Complete Remission (CR) Plus CR With Partial Hematologic Recovery (CRh) Rate |
CR plus CRh will be defined as the proportion of participants whose best overall response (BOR) is CR plus CRh. BOR will be defined as the best response recorded from the first dose of study drug until data cut or the initiation of new anticancer treatment. |
Approximately 24 months |
|
Primary |
Part 3 MDS Cohort: Modified Overall Response (mOR) Rate |
The mOR will be defined as the proportion of participants whose BOR is achieving CR, marrow complete remission (mCR), or partial remission (PR) at any time point during the study for myelodysplastic/myeloproliferative neoplasm (MDS/MPN). |
Approximately 24 months |
|
Primary |
Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to the last quantifiable (AUC0-t) Of BGB-11417 When Co-administered With Posaconazole |
|
Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose) |
|
Primary |
Part 3 AML Cohort (DDI Sub-cohort): Maximum Observed Plasma Concentration (Cmax) Of BGB-11417 When Coadministered With Posaconazole |
|
Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose) |
|
Primary |
Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to infinity (AUC0-infinity) Of BGB-11417 When Co-administered With Posaconazole |
|
Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, , 4, 6, 8, and 24 hours postdose) |
|
Primary |
Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number Of Participants Experiencing DLTs |
|
Cycle 2 |
|
Primary |
Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number of Participants Experiencing TEAEs |
|
Approximately 24 months |
|
Secondary |
Parts 1 And 2 AML Cohort: CR Plus CRh Rate |
|
Approximately 24 months |
|
Secondary |
Parts 1 And 2 MDS Cohort: mOR Rate |
|
Approximately 24 months |
|
Secondary |
Parts 1 And 2: Cmax Of Azacitidine When Coadministered With BGB-11417 |
|
Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose |
|
Secondary |
Parts 1 And 2: t1/2 Of Azacitidine When Coadministered With BGB-11417 |
|
Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose |
|
Secondary |
Parts 1 And 2: AUC From Time Zero To Time t (AUC0-t) Of Azacitidine When Coadministered With BGB-11417 |
|
Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose |
|
Secondary |
Parts 1 And 2: AUC From Time Zero To Infinity (AUC0-inf) Of Azacitidine When Coadministered With BGB-11417 |
|
Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose |
|
Secondary |
Parts 1 And 2: Apparent Total Clearance Of Drug From Plasma After Oral Administration (CL/F) Of Azacitidine When Coadministered With BGB-11417 |
|
Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose |
|
Secondary |
Parts 1 And 2: Apparent Volume Of Distribution (Vz/F) Of Azacitidine When Coadministered With BGB-11417 |
|
Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose |
|
Secondary |
Parts 1 And 2: Steady-state AUC From Time Zero To Time Of Last Measurable Concentration (AUClast,ss) Of BGB-11417 When Coadministered With Azacitidine |
|
Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose |
|
Secondary |
Parts 1 And 2: Steady-state Cmax (Cmax,ss) Of BGB-11417 When Coadministered With Azacitidine |
|
Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose |
|
Secondary |
Parts 1 And 2: Steady-state Trough Plasma Concentration (Ctrough,ss) Of BGB-11417 When Coadministered With Azacitidine |
|
Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose |
|
Secondary |
Parts 1 And 2: Steady-state Time To Maximum Observed Plasma Concentration (tmax,ss) Of BGB-11417 When Coadministered With Azacitidine |
|
Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose |
|
Secondary |
Part 3: Number Of Participants Receiving BGB-11417 In Combination With Azacitidine Experiencing TEAEs |
|
Approximately 24 months |
|
Secondary |
Part 3: Complete Response |
CR will be defined as the proportion of participants whose BOR is CR. BOR will be defined as the best response recorded from the first dose of study drug until data cut or the initiation of new anticancer treatment. |
Approximately 24 months |
|
Secondary |
Part 3 AML Cohort: CR With Incomplete Hematologic Recovery (CRi) Rate |
CRi will be defined as the proportion of participants whose BOR is CRi. |
Approximately 24 months |
|
Secondary |
Part 3 AML Cohort: Overall Response Rate (ORR) |
The ORR will include participants whose BOR include CR, CRi, PR, and morphologic leukemia-free state. |
Approximately 24 months |
|
Secondary |
Part 3 AML Cohort: Duration Of Response (DOR) |
DOR will be defined as the time from the first response to disease progression documented after treatment initiation or death, whichever occurs first. DOR will include CR, CR plus CRi, overall response (OR), and CR plus CRh. |
Approximately 24 months |
|
Secondary |
Part 3 AML Cohort: Time To Response (TTR) |
TTR will be defined as the time from treatment initiation to the first documented response and will include CR, CR plus CRi, OR, and CR plus CRh. |
Approximately 24 months |
|
Secondary |
Part 3 AML Cohort: Event-free Survival (EFS) |
EFS will be defined as the time from treatment initiation to disease progression, treatment failure, relapse (hematologic relapse for AML) for those who have treatment success, or death due to any cause, whichever happens first. |
Approximately 24 months |
|
Secondary |
Part 3 AML Cohort: Overall Survival (OS) |
OS will be defined as the time from treatment initiation to death. OS will be analyzed using the same methods as the EFS analysis except for the censoring rules. |
Approximately 24 months |
|
Secondary |
Part 3 AML Cohort: Number Of Participants Receiving BGB-11417 In Combination With Posaconazole Experiencing TEAEs |
|
Approximately 24 months |
|
Secondary |
Part 3 AML Cohort: Number of Participants with Transfusion Independence |
Transfusion independence will be defined as the proportion of participants whose BOR is transfusion independence. Transfusion independence will need to last for at least 56 consecutive days postbaseline. |
Approximately 24 months |
|
Secondary |
Part 3 MDS Cohort: Number Of Participants With Hematological Improvement-erythroid (HI-E) |
The proportion of participants whose BOR is HI-E |
Approximately 24 months |
|
Secondary |
Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-platelet (HI-P) |
The proportion of participants whose BOR is HI-P |
Approximately 24 months |
|
Secondary |
Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-neutrophil (HI-N) |
The proportion of participants whose BOR is HI-N will be reported. |
Approximately 24 months |
|
Secondary |
Part 3 MDS Cohort: Number of participants with Transfusion Independence |
Transfusion independence will be defined as the proportion of participants whose BOR is transfusion independence. Transfusion independence will need to last for at least 56 consecutive days postbaseline. |
Approximately 24 months |
|
Secondary |
Part 3: Ctrough,ss Of BGB-11417 When Coadministered With Azacitidine |
|
Cycle 1 Day 1 and Cycle 2 Day 5 (predose and 4 and 6 hours postdose) |
|
Secondary |
Part 3 MDS cohort: Partial Hematologic Recovery CRh |
Proportion of participants with partial hematologic recovery will be reported |
Approximately 24 months |
|
Secondary |
Part 3 AML (Treated with Monotherapy): Complete Response + Morphologic complete Remission with Partial Hematologic Recovery |
Proportion of participants with Complete Response + Morphologic complete Remission with Partial Hematologic Recovery will be reported. |
Approximately 24 months |
|
Secondary |
Part 3 AML (Treated with Monotherapy): Steady State trough plasma concentration of BGB-11417 |
|
Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 4, 6, 8, and 24 hours postdose) |
|
Secondary |
Part 3 MDS (Treated with Monotherapy): Modified Overall Response |
Proportion of participants with modified overall response including CR, marrow CR (mCR) or partial remission (PR) |
Approximately 24 months |
|
Secondary |
Part 3 MDS (Treated with Monotherapy): Steady State trough plasma concentration of BGB-11417 |
|
Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 4, 6, 8, and 24 hours postdose) |
|